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Background: Autosomal recessive hypercholesterolemia (ARH) is an extremely rare inherited 
hypercholesterolemia, the cause of which is mutations in low-density lipoprotein (LDL) receptor 
adaptor protein 1 (LDLRAP1) gene.  
Methods: A total of 146 heterozygous familial hypercholesterolemic (FH) patients with a mutation 
in LDLR gene were screened for genes encoding proprotein convertase subtilisin/kexin type 9 
(PCSK9) and LDLRAP1.  
Results: Among the 146 subjects, we identified a 79-year-old Japanese female with double 
mutations in LDLR gene (c.2431A>T) and LDLRAP1 gene (c.606dup). Two other relatives with 
double mutations in those genes in her family were also identified. Although the proband exhibited 
massive Achilles tendon xanthoma and coronary and aortic valvular disease, serum LDL-C level of 
subjects with double mutations was similar with that of subjects with single LDLR mutation 
(284.0±43.5 versus 265.1±57.4mg/dl). 
Conclusion: Additional mutation in LDLRAP1 may account for severer phenotype in terms of 
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Familial hypercholesterolemia (FH) is an inherited disease characterized by the triad of (1) 
hypercholesterolemia due to a high level of plasma LDL, (2) tendon xanthomas and (3) premature 
coronary artery disease [1]. Patients with homozygous FH have been defined as who have two 
mutant alleles of either of three following FH-associated genes: LDLR, apolipoprotein B (ApoB) 
gene and proprotein convertase subtilisin/kexin type 9 (PCSK9) [2]. Previously, we identified 
several homozygous FH patients who possessed double heterozygous mutations in LDLR gene and 
PCSK9 gene in relatively mild phenotypic patients compared with those with double mutations in 
LDLR gene [3]. In addition to autosomal dominant types of FH, recessive form of FH-associated 
gene was identified in 1992 [4]. The null mutations in the LDL receptor adaptor protein 1 
(LDLRAP1) gene, which serves as an adaptor for LDLR endocytosis in the liver, causes autosomal 
recessive hypercholesterolemia (ARH) [5]. It is described that several heterozygous LDLRAP1 
mutation carrier showed elevated LDL-C levels [6, 7]. However, there is no data on clinical 
significance of adding a mutation in LDLRAP1 gene onto single LDLR gene mutation.    
 
2. Methods 
2.1. Study subjects 
This study was approved by the Ethics Committee of Graduate School of Medical Science, 
Kanazawa University, and all study subjects gave their written informed consent to participate. We 
examined consecutive unrelated 146 subjects with a single mutation in the LDLR gene (male=96, 
mean age=56.5±16.0, mean LDL-C=265.6±57.7mg/dl) since 2003 to 2008. All the participants 
were free from unstable or acute cardiovascular diseases. All the lipid-lowering therapy had been 
transiently suspended for one to three months to diagnose lipid disorders correctly. Although it has 
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been described the existence of the rebound effect after transient suspension of statin therapy [8], it 
is also reported that short-term suspension of statins is safe for at least patients with stable 
cardiovascular disease [9]. Complications related to this short-term suspension of lipid-lowering 
therapy have not been observed so far in our institute. The characteristics of the study subjects were 
listed in Table 1 and supplementary Table. 
2.2 Biochemical analysis 
Serum concentrations of total cholesterol (TC), triglyceride (TG), and high-density lipoprotein 
cholesterol (HDL-C) were determined enzymatically. LDL-C concentrations were derived using the 
Friedewald formula. Apolipoprotein E (ApoE) phenotype was separated by isoelectric focusing and 
detected by Western blot with apoE polyclonal antibody (phenotyping apoE IEF system, JOKOH, 
Tokyo, Japan). Plasma cholesteryl ester transfer protein (CETP) levels were determined by a 
specific ELISA [10]. 
2.3. Genetic analysis 
Genomic DNA was isolated from peripheral blood white blood cells according to standard 
procedures and was used for PCR. Primers for the study were as used previously [3, 11]; PCR 
products were purified by Microcon (Millipore Corp., Bedford, MA) and used as templates for 
direct sequencing. DNA sequencing was carried out according to the manufacturer’s instructions 
using a dye terminator method (ABI PRISMTM 310 Genetic Analyzer (PerkinElmer Biosystems, 
Waltham, MA). We screened the study subjects for all coding region of PCSK9 and LDLRAP1 
genes as candidate genes that could affect their lipid profile and clinical phenotype. In addition, we 
analyzed the two common mutations of the CETP gene (c.1321+1G>A, previously described as 
Int14A and c.1376A>G, previously described as D442G) among Japanese population as previously 




3. Results  
3.1.  Biochemical analysis 
Serum lipids and apolipoproteins in the proband and her pedigree are presented in Table 2.  
3.2. Sequence of LDLR gene 
Mutation in LDLR gene of the proband (c.2431A>T) was one of the most common mutations in 
Japan [13] (Supplementary Figure 1A). 
3.3. Sequence analysis of candidate genes for inherited hypercholesterolemia 
Although there was no genetic abnormality in her PCSK9 gene, we identified another 
heterozygous mutation in her LDLRAP1 gene (c.606dup, Supplementary Figure 1B).  
3.4. Clinical course of the proband 
At the age of 67, she was diagnosed as FH due to severe hypercholesterolemia with Achilles’ 
tendon thickness (Supplementary Figure 2). Initial levels of TC, TG, and HDL-C concentrations 
were 367, 108, and 46 mg/dl, respectively under statin therapy (pravastatin 20mg daily). She 
underwent coronary artery bypass graft surgery at the age of 70 due to angina pectoris. The more 
intensive cholesterol lowering therapy using atorvastatin 20mg daily was introduced for secondary 
prevention of cardiovascular disease. She was referred to our hospital for further examination of her 
hypercholesterolemia and coronary artery disease at the age of 78. Although her coronary 
atherosclerosis including bypass grafts did not progress substantially during 8 years (Supplementary 
Figure 3), severe aortic valve stenosis developed causing her chest pain (Supplementary Figure 4). 
Although aortic valve replacement surgery was recommended, she refused due to potential 
complications derived from extreme high age. 
3.5. Family study 
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Family study was performed as intensively as possible to find another family member with 
LDLR or LDLRAP1 mutation. We identified two other relatives with double mutations, and one 
obligate carrier who died suddenly probably due to cardiac event in his forties (Figure 2). 
3.6. Genetic analysis for CETP gene 
   There was no carrier for both of common CETP gene mutation in this family.  
 
4. Discussion 
Patients with homozygous FH have two mutant alleles of either of three FH-associated genes 
(FH genes), namely LDLR, apolipoprotein B-100 and PCSK9 genes. In addition to those dominant 
form inherited gene mutation recessive form of null mutations in LDLRAP1 gene also causes FH 
(autosomal recessive hypercholesterolemia:ARH). There are few published data about the clinical 
characteristics of LDLRAP1 heterozygous mutation carriers because of rarity of this disorder. 
Previously, we have shown that c.606dup mutation carriers in LDLRAP1 gene had elevated LDL-C 
concentrations compared with non-carrier family members [14], suggesting that “autosomal 
recessive hypercholesterolemia “ is not necessarily a correct term.  
In this paper, we report the first family which exhibit double mutations in LDLR and 
LDLRAP1 gene with severe xanthomas and coronary artery disease as well as the episode of 
ventricular fibrillation due to aortic valve stenosis. Besides the proband, we found two other 
relatives in her family with the same double mutations in LDLR and LDLRAP1 gene.  
Some of the pedigrees, including double mutation carriers exhibit relatively high HDL-C level. 
Previously, we reported that the CETP gene mutations causing higher HDL-C levels are common in 
Japan [12]. However, there was no carrier of two common CETP gene mutations (c.1321+1G>A 
and c.1376A>G) among this family member. The plasma levels of CETP of this family member 
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were within normal limit, suggesting absence of CETP deficiency. It has been reported that the 
causes of high HDL-C level were quite heterogeneous [15]. Thus, we cannot exclude the possibility 
that unknown genetic factors may be involved in their high HDL-C levels. Another possibility of 
higher HDL-C is their excessive alcohol drinking. The pedigrees whose HDL-C levels were more 
than 90 mg/dl (II-1 and II-2) were both heavy drinkers (ethanol > 120g/day). 
In conclusion, we report the first family with double mutation in LDLR and LDLRAP1 genes 
associated with autosomal dominant and recessive form of hypercholesterolemia. Although the 
proband exhibited massive Achilles tendon xanthoma and severe coronary and aortic valvular 
disease, serum LDL-C level of subjects with double mutations was similar with that of subjects with 
single LDLR mutation. We suggest that an additional mutation in LDLRAP1 may account for 
severer phenotype in terms of xanthoma and atherosclerotic cardiovascular disease in FH patients.  
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Fig. 1. Clinical course of the proband 
Plasma concentration of the total cholesterol (solid circle), triglyceride (open circle), and HDL-C 
(open triangle) in the proband, and the major clinical events were illustrated. CABG; coronary 
artery bypass grafting, VF; ventricular fibrillation.  
 
Fig. 2. Pedigree of the proband 
Half-filled by black squares or circles indicate the heterozygous mutation carrier in LDLR 
(c.2431A>T). Half-filled by brown squares or circles indicate the heterozygous mutation carrier in 
LDLRAP1 (c.606dup). Square with a dot indicates the obligate carrier. Open squares or circles 
indicate unaffected subjects. Hatched squares or circles indicate the genetically unknown subjects. 
 
Table 1













Clinical data of the pedigree
Subject (gender) I-1 (female) II-1 (male) II-2 (male) III-1 (female) IV-1 (male) IV-2 (male)
LDLR genotype W/M1 W/W W/M1 W/M1 W/W W/M1
LDLRAP1 genotype W/M2 W/W W/M2 W/M2 W/W W/W
Age (yr) 79 51 45 32 3 2
ATT (mm) 24 n.d. n.d. 13 n.d. n.d.
TC (mg/dl) 393 224 365 392 166 286
TG (mg/dl) 165 46 63 60 39 92
HDL-C (mg/dl) 42 97 96 61 59 62
LDL-C (mg/dl) 318 118 235 299 99 205
ApoA-I (mg/dl) 114 n.d. n.d. 136 136 141
ApoB (mg/dl) 232 n.d. n.d. 174 68 129
ApoE phenotype 3/3 3/3 3/3 3/3 3/3 3/3
CETP (μg/ml) 4.2 2.0 3.2 2.6 n.d. n.d.
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Supplementary Table. Type of LDLR mutations of screened FH subjects. c 2431A>T mutation was the most
Location Nucleotide change Mutation type
Effect on protein 
(mutation class)
Numbers 
of patients TC TG HDL-C LDL-C
Intron 1-Intron 3 c.68-?_313+?del Large deletion Binding defective (3) 14 316±61 122±100 48±13 244±60
Exon 2 c.137G>A Missense Cys-Tyr 1 342 124 45 272
Exon 4 c.344G>A Missense Arg-His 2 300±1 300±1 300±1 300±1
Exon 4 c.611G>C Missense Cys-Ser 4 324±67 144±26 45±18 256±59
Exon 5 c.796G>A Missense Asp-Asn 3 319±38 87±45 50±12 252±38
Intron 7-Intron 14 c.941-?_2140+?del Large deletion
Binding/recycling 
defective (3/5) 2 346±118 92±21 49±5 279±118
Exon 9 c.1297G>C Missense Asp-His 6 366±56 105±60 47±11 297±51
Exon 10 c.1567G>A Missense Val-Met (2A) 2 336±44 120±60 47±15 255±60
Exon 11 c.1689dupC Insertion Frameshift/stop 2 315±60 207±142 56±21 223±54
Exon 13 c.1871_1873delTCA Deletion 602 Ile deletion 4 335±42 139±43 42±10 264±46
Exon 14 c.2054C>T Missense Pro-Leu (2B) 19 349±46 162±125 40±13 288±55
Exon 15-Exon 18 c.2141-?_2583+?del Large deletion Truncated protein 14 322±58 110±48 48±13 252±55
Intron 15 c.2312-3C>A Splicing Exon 16 skip 12 335±68 89±65 43±7 258±61
Exon 17 c.2431A>T Nonsense Lys-stop 61 334±55 126±60 48±21 257±63
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Supplementary Figure 1. DNA sequence data of the proband (left panel) and a control subject 
(right panel) for the LDLR gene exon 17 (A) and LDLRAP1 gene exon 6 (B). (A): Heterozygosity 
for a substitution of adenine to thymine was shown in the proband. (B): Heterozygosity for an extra 
cytosine insertion mutation in eight sequential cytosines between the nucleotide positions 599 and 606 
(nucleotides are numbered from the first nucleotide that encodes the starting methyonine codon) was 
shown in the proband, with another single nucleotide polymorphism (c.604 C>T) in this lesion. 
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Supplementary Figure 2. X-ray of proband’s Achilles’ tendon. The Achilles’ tendon thickness 




Supplementary Figure 3. Coronary CT of the proband. Bypass grafts (RITA-RCA, 





Supplementary Figure 4. Echocardiogram of the proband. The peak velocity measured by 
continuous-wave Doppler through the aortic valve also increased from 5.05m/s, which corresponded to 
102 mmHg of pressure gradient from the left ventricle to aorta. LV; left ventricle, LA; left atrium, Ao; 
aorta. 
